The urgent need for innovative technologies to accelerate the development of life-saving %Cancer therapies has never been more critical. With millions of lives and billions of dollars at stake, the potential...
Novel Natrunix Treatment Shows Promise in Combination Chemotherapy for Treatment of Pancreatic Cancer...
XBiotech Manufacturing Antibody Drug for Janssen Research & Development, LLC (Janssen), One of the Janssen Pharmaceutical Companies of Johnson & Johnson...
Natrunix-SQ, A True Human Antibody Therapy Discovered and Manufactured at XBiotech, Is Aimed as a Breakthrough Treatment for Arthritic Disease...
Company Commencing Phase I/II Study to Test Safety and Efficacy of its New Drug Candidate to Reduce Brain Injury After Stroke...
AUSTIN, Texas, Sept. 08, 2021 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) (“XBiotech”) today announced that Benjamin Musher M.D., will chair XBiotech’s clinical program for pancreatic cancer....
Dr. Ziats Joins Clinical Team Involved in Launch and Management of Clinical Studies Across Multiple Indications
Company distributed USD $75 Million to Shareholders
AUSTIN, Texas, July 06, 2021 (GLOBE NEWSWIRE) -- XBiotech Inc.’s (NASDAQ: XBIT) (“XBiotech”) Board of Directors has declared an extraordinary cash dividend of approximately $2.50 per share, or...
Company Has Now Received a Total of $750 million for Sale of Its True Human Antibody
XB2001 Is a Novel Therapy that Interrupts Inflammation to Potentially Block Growth and Spread of Tumors and to Reduce Toxicity of Chemotherapy Treatment
XBiotech to Supply INSERM its New Drug to Use in Combination Therapy for Treating Advanced Colorectal Cancer